Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 643

The DOI matches its OpenAlex record; 61 of the 61 references it cites were found in a registry or an index.

Diabetic Dyslipidemia: Causes and Consequences

Ira J. Goldberg·2001·The Journal of Clinical Endocrinology & Metabolism

Abstract

More cardiovascular disease occurs in patients with either type 1 or 2 diabetes. The link between diabetes and atherosclerosis is, however, not completely understood. Among the metabolic abnormalities that commonly accompany diabetes are disturbances in the production and clearance of plasma lipoproteins. Moreover, development of dyslipidemia may be a harbinger of future diabetes. A characteristic pattern, termed diabetic dyslipidemia, consists of low high density lipoprotein (HDL), increased triglycerides, and postprandial lipemia. This pattern is most frequently seen in type 2 diabetes and may be a treatable risk factor for subsequent cardiovascular disease. The pathophysiological alterations in diabetes that lead to this dyslipidemia will be reviewed in this article. Defects in insulin action and hyperglycemia could lead to changes in plasma lipoproteins in patients with diabetes. Alternatively, especially in the case of type 2 diabetes, the obesity/insulin-resistant metabolic disarray that is at the root of this form of diabetes could, itself, lead to lipid abnormalities exclusive of hyperglycemia. Type 1 diabetes, previously termed insulin-dependent diabetes mellitus, provides a much clearer understanding of the relationship among diabetes, insulin deficiency, and lipid/lipoprotein metabolism. In poorly controlled type 1 diabetes and even ketoacidosis, hypertriglyceridemia and reduced HDL commonly occur (1). Replacement of insulin in these patients may correct these abnormalities, and well controlled diabetics may have increased HDL and lower than average triglyceride levels. The lipoprotein abnormalities commonly present in type 2 diabetes, previously termed noninsulin-dependent diabetes mellitus, include hypertriglyceridemia and reduced plasma HDL cholesterol. In addition, low density lipoprotein (LDL) are converted to smaller, perhaps more atherogenic, lipoproteins termed small dense LDL (2). In contrast to type 1 diabetes, this phenotype is not usually fully corrected with glycemic control. Moreover, this dyslipidemia often is found in prediabetics, patients with insulin resistance but normal indexes of plasma glucose (3). Therefore, abnormalities in insulin action and not hyperglycemia per se are associated with this lipid abnormality. In support of this hypothesis, some thiazoladinediones improve insulin actions on peripheral tissues and lead to a greater improvement in lipid profiles than seen with other glucose-reducing agents (4). Several factors are likely to be responsible for diabetic dyslipidemia: insulin effects on liver apoprotein production, regulation of lipoprotein lipase (LpL), actions of cholesteryl ester transfer protein (CETP), and peripheral actions of insulin on adipose and muscle. A number of studies using tracer kinetics in humans have demonstrated that liver production of apolipoprotein B (apoB), the major protein component of very low density lipoprotein (VLDL) and LDL, is increased in type 2 diabetes. ApoB is a large (>500-kDa) protein whose production is not modulated at the level of protein synthesis. In animals and cultured liver cells, transcription of the apoB gene is not remarkably altered by dietary changes and diabetes. Rather, a large amount of newly synthesized protein is degraded either during or immediately after translation. This degradation is prevented when lipid is added to the protein; this occurs via the actions of microsomal triglyceride transfer protein (the protein that is defective in patients with apobetalipoproteinemia). Thus, lipid regulates apoB production. Increased lipolysis in adipocytes due to poor insulinization results in increased fatty acid release from fat cells. The ensuing increase in fatty acid transport to the liver, which is a common abnormality seen in insulin-resistant diabetes, may cause an increase in VLDL secretion. Tissue culture (5), animal experiments (6), and human studies (7) suggest that fatty acids modulate liver apoB secretion. A second regulatory process may be a direct effect of insulin on liver production of apoB and other proteins involved in degradation of circulating lipoproteins. In some studies insulin directly increased degradation of newly synthesized apoB (8). Therefore, insulin deficiency or hepatic insulin resistance may increase the secretion of apoB. Insulin may modulate the production of a number of other proteins that affect circulating levels of lipoproteins. These include apoCIII (9), a small apoprotein that may increase VLDL by preventing the actions of LpL and inhibiting lipoprotein uptake via the LDL receptor-related protein (LRP). Hepatic lipase is an enzyme synthesized by hepatocytes that hydrolyzes phospholipids and triglycerides on HDL and remnant lipoproteins. Some (10, 11), but not all (12), studies suggest that this enzyme is reduced by insulin deficiency. One effect of hepatic lipase deficiency is to decrease the clearance of postprandial remnant lipoproteins (see below). LpL is the major enz

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1210/jc.86.3.965

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 643

Metadata

Authors
Goldberg, I. J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
Oxford University Press
Published
2001-03-01
Volume
86
Issue
3
Pages
965-971
ISSN
0021-972X (ISSN-L)
OpenAlex
W2003771230
Cited by
643
References
61
FWCI
6.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetic Dyslipidemia: Causes and Consequences. https://app.cochat.ai/papers/10.1210/jc.86.3.965
The paper
Goldberg, I. J. (2001). Diabetic Dyslipidemia: Causes and Consequences. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.86.3.965

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.